⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for btk

Every month we try and update this database with for btk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerNCT05106296
Ependymoma
Medulloblastoma
Glioblastoma
Primary Brain T...
Ibrutinib
Indoximod
Cyclophosphamid...
Etoposide
12 Years - 25 YearsAugusta University
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLNCT03740529
Chronic Lymphoc...
Waldenstrom Mac...
Mantle Cell Lym...
Marginal Zone L...
B-cell Lymphoma
Small Lymphocyt...
Pirtobrutinib
Venetoclax
Rituximab
18 Years - Eli Lilly and Company
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaNCT02180711
Non Hodgkin Lym...
acalabrutinib
rituximab (IV)
Lenalidomide
18 Years - Acerta Pharma BV
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaNCT04624906
Waldenstrom Mac...
Acalabrutinib
Bendamustine
Rituximab
18 Years - Sunnybrook Health Sciences Centre
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerNCT05106296
Ependymoma
Medulloblastoma
Glioblastoma
Primary Brain T...
Ibrutinib
Indoximod
Cyclophosphamid...
Etoposide
12 Years - 25 YearsAugusta University
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaNCT02180724
Waldenström Mac...
Acalabrutinib (...
Acalabrutinib (...
18 Years - 130 YearsAcerta Pharma BV
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaNCT04624906
Waldenstrom Mac...
Acalabrutinib
Bendamustine
Rituximab
18 Years - Sunnybrook Health Sciences Centre
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLNCT03740529
Chronic Lymphoc...
Waldenstrom Mac...
Mantle Cell Lym...
Marginal Zone L...
B-cell Lymphoma
Small Lymphocyt...
Pirtobrutinib
Venetoclax
Rituximab
18 Years - Eli Lilly and Company
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesNCT02362035
Follicular Lymp...
CLL
Small Lymphocyt...
Richter's Syndr...
Mantle Cell Lym...
Indolent Non Ho...
Waldenström Mac...
Multiple Myelom...
Hodgkin Lymphom...
Burkitt Lymphom...
Marginal Zone L...
Mediastinal Lar...
Hairy Cell Leuk...
Acalabrutinib
Pembrolizumab
18 Years - Acerta Pharma BV
Safety and Activity of SNX-5422 Plus Ibrutinib in CLLNCT02914327
Cancer
SNX-5422 plus i...
18 Years - Esanex Inc.
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaNCT02213926
Mantle Cell Lym...
ACP-196 (acalab...
18 Years - 130 YearsAcerta Pharma BV
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesNCT02362035
Follicular Lymp...
CLL
Small Lymphocyt...
Richter's Syndr...
Mantle Cell Lym...
Indolent Non Ho...
Waldenström Mac...
Multiple Myelom...
Hodgkin Lymphom...
Burkitt Lymphom...
Marginal Zone L...
Mediastinal Lar...
Hairy Cell Leuk...
Acalabrutinib
Pembrolizumab
18 Years - Acerta Pharma BV
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSNCT04477291
Acute Myeloid L...
Myelodysplastic...
CG-806
18 Years - Aptose Biosciences Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: